CVRx, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CVRX research report →
Range $2 – $5
Price Chart
About the company
CVRx, Inc. is a commercial-stage medical technology company focused on innovating, producing, and bringing to market neuromodulation solutions designed for individuals battling cardiovascular diseases. Its principal offering, Barostim, is an advanced neuromodulation device specifically indicated to ameliorate symptoms for patients diagnosed with heart failure characterized by reduced ejection fraction, often referred to as systolic heart failure.
- CEO
- Kevin Hykes
- IPO
- 2021
- Employees
- 223
- HQ
- Minneapolis, MN, US
Get TickerSpark's AI analysis on CVRX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $14.27M
- P/E
- -0.25
- PEG
- -0.64
- P/S
- 0.24
- P/B
- 0.99
- EV/EBITDA
- -0.32
- Div Yield
- 0.00%
- Gross Margin
- 86.90%
- Op Margin
- -81.90%
- Net Margin
- -88.28%
- ROE
- -208.45%
- ROIC
- -65.46%
Latest fiscal year · YoY change
- Revenue
- $56.65M+10.4%
- Gross Profit
- $48.34M+12.5%
- Op Income
- $-51,265,000
- Net Income
- $-53,306,000+11.1%
- EPS
- $-2.04+23.0%
- OCF Growth
- -2.6%
- FCF Growth
- -0.6%
- 52W High
- $10.28
- 52W Low
- $0.50
- 50D MA
- $1.62
- 200D MA
- $4.85
- Beta
- 0.76
- RSI (14)
- 19
- Avg Volume
- 744.45K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
CVRx missed its earlier revenue outlook as Medicare Advantage reimbursement delays, physician turnover, and uneven sales execution pressured third-quarter growth, though gross margin stayed strong at 87% and management expects cost cuts to support a lower 2026 revenue base.· November 5, 2026
- Q3 revenue was $13.8 million, down 6.1% year over year, with U.S. revenue down 4% and Europe down 27%.
- Gross margin remained 87%, showing pricing/mix stability despite softer top-line growth.
- Management cut full-year 2026 revenue guidance to $56 million-$57 million from $58 million-$60 million and guided Q4 revenue to $11.7 million-$12.7 million.
- The biggest issue remains reimbursement, especially with the largest Medicare Advantage payer, where 30-day approval rates fell to about 12% from 83% in 2025.
- CVRx said it has 2 written Medicare Advantage coverage policies covering 21% of MA lives, improved traditional Medicare payment consistency, and is seeing better stability in its field force.
Total revenue was $13.8 million, down $900 thousand or 6.1% year over year. U.S. revenue was $13.0 million, down $500 thousand or 4%, on 412 U.S. revenue units versus 420 last year; Europe revenue was $900 thousand, down $300 thousand or 27%, on 38 units versus 50. Gross profit was $12.0 million, down $800 thousand or 6%, and gross margin was 87%, unchanged from a year ago. Net loss was $14.2 million, or $0.52 per share, versus a net loss of $12.9 million, or $0.49 per share. Cash and cash equivalents were $58.7 million at quarter-end, and the company said it has at least 18 months of cash runway excluding any ATM proceeds. For 2026, CVRx lowered full-year revenue guidance to $56 million-$57 million, expects Q4 revenue of $11.7 million-$12.7 million, and reiterated full-year gross margin of 86%-87% and operating expenses of $99 million-$101 million.
Kevin Hykes said the quarter reflected three main headwinds: reimbursement, physician champion turnover, and field execution. He emphasized that the company is actively appealing denials, adding reimbursement managers, stabilizing the sales organization, and building broader referral networks to make Barostim adoption more consistent across regions. He also sounded constructive on the clinical side, pointing to strong HFSA data, including the Rebalance real-world cohort and interest in Benefit HF, while noting discussions with the FDA about a potential real-world-evidence-based PMA supplement.
Jared Oasheim said revenue came in at $13.8 million, with gross profit of $12.0 million and gross margin of 87%. He highlighted that operating expenses were $25.1 million in the quarter and about $77 million year to date, with SG&A up to $22.4 million mainly from legal, travel, and consulting costs, while R&D fell to $2.7 million. He noted cash and cash equivalents of $58.7 million and said the company raised about $6 million through its ATM during the quarter, while also stating the cost actions provide at least 18 months of runway. He added that full-year 2026 revenue guidance was reduced to $56 million-$57 million, Q4 revenue is expected at $11.7 million-$12.7 million, and full-year OpEx remains expected at $99 million-$101 million after severance charges and cost reductions.
Analysts focused on what was embedded in Q4 guidance, how the headwinds may flow into 2027, and whether the reimbursement problem with the largest Medicare Advantage payer can be fixed. Management said the issue is the payer’s lack of a written policy and a sharp deterioration in approval behavior, and that the company’s remedy is to continue appealing denials through the ALJ process until the payer is pressured to adopt a policy, as happened with Humana. They also said the company is not giving detailed 2027 OpEx guidance yet, but the cost actions create a lower cost base going forward. On the higher-than-usual implant timing, management said some demand moved between quarters, which helped explain Q3 versus Q4 timing, but did not quantify the impact further.
Management said it now has 2 written Medicare Advantage coverage policies, covering 21% of covered lives, and that traditional Medicare claims in Q1 2026 were paid at a 100% rate for the first time. Gross margin stayed at 87%, and the company said its most stable regions are still growing procedures by more than 20% on average. Executives also sounded upbeat about clinical evidence, citing HFSA presentations, the Rebalance real-world cohort, and strong interest in Benefit HF.
The core risk is reimbursement: the largest Medicare Advantage payer’s 30-day approval rate fell to about 12%, and management said many denials are not being appealed by providers, reducing access. Physician champion turnover is still disrupting programs, with management saying it can take 3 to 4 quarters to rebuild momentum after a key doctor leaves. The company also acknowledged uneven execution across its 9 U.S. regions, with 4 regions lagging because of lower tenure and less experienced leadership.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 60.8%
- Shares Outstanding
- 28.48M
- Float Shares
- 17.32M
of shares held by institutions
92 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for CVRX, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Richard BlumenthalSenate · CT | Sell | Jul 8, 26 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Johnson & Johnson | 4.02M | 0 |
| Nea Management Company, LLC | 1.95M | ▼ 71.64K |
| Blackrock, Inc. | 1.29M | ▲ 41.33K |
| Royal Bank Of Canada | 1.23M | ▲ 526.26K |
| Vanguard Group Inc | 1.12M | ▲ 30.44K |
| Gsk PLC | 1.01M | 0 |
| Vanguard Capital Management LLC | 902.43K | ▼ 8.15K |
| Silvercrest Asset Management Group LLC | 878.11K | ▲ 306.09K |
| Renaissance Technologies LLC | 435.40K | ▲ 205.40K |
| Geode Capital Management, LLC | 423.09K | ▼ 17.70K |
| Pfm Health Sciences, LP | 369.57K | ▲ 369.57K |
| State Street Corp | 346.52K | ▼ 19.83K |
Held by 93 ETFs
Biggest fund positions in CVRX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 9, 26 | Landry John | other | 186,447 |
| Nov 9, 26 | Landry John | other | 41,433 |
| Nov 6, 26 | Landry John | other | 0 |
| Aug 13, 26 | Binkowski Brent | buy | 26,223 |
| Aug 12, 26 | Binkowski Brent | sell | 1,309 |
| Jun 1, 26 | Nielsen Kirk G. | other | 11,182 |
| Jun 1, 26 | Nielsen Kirk G. | other | 8,720 |
| Jun 1, 26 | Jain Mudit K. | other | 8,720 |
| Jun 1, 26 | Jain Mudit K. | other | 11,182 |
| Jun 1, 26 | SLATTERY JOSEPH P | other | 8,720 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CVRX coverage
Recent articles, reports, and earnings notes.
No research on CVRX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CVRX report →ROSEN, TRUSTED INVESTOR COUNSEL, Encourages CVRx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CVRX
newsfilecorp.com · Nov 21
What's Next for CVRx, Inc. Shareholders After 59.76% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff Deadline
prnewswire.com · Nov 20
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages CVRx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CVRX
newsfilecorp.com · Nov 20
Robbins LLP Urges CVRX Shareholders Who Lost Money Investing in CVRx, Inc. to Contact the Firm for About Leading the Class Action
prnewswire.com · Nov 20
ROSEN, A LEADING LAW FIRM, Encourages CVRx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CVRX
globenewswire.com · Nov 19
CVRx ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against CVRx Inc. and Encourages Investors to Contact the Firm
globenewswire.com · Nov 19
What Does CVRx, Inc.'s 59.76% Stock Drop Mean for Investors? The Law Offices of Howard G.
prnewswire.com · Nov 19
SHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against CVRx, Inc. (NASDAQ: CVRX) — Investors Who Suffered Losses Are Encouraged to Contact the Firm
globenewswire.com · Nov 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.